Lived Experience of Advanced Hybrid Closed-Loop Versus Hybrid Closed-Loop: Patient-Reported Outcomes and Perspectives
Publication: Diabetes Technology & Therapeutics
Volume 23, Issue Number 12
Abstract
This article reports on the lived experience of Medtronic advanced hybrid closed-loop (AHCL) in comparison to first generation hybrid closed-loop (HCL) in a randomized, open-label, two-period crossover trial. Patient-reported outcome (PROs) measures were administered before randomization and at the end of each study period in 113 adolescents and young adults with type 1 diabetes. Glucose monitoring satisfaction subscales for emotional burden and behavioral burden improved significantly (P < 0.01) over time with use of AHCL versus HCL and co-occurred with glycemic improvements (reduced percent time above 180 mg/dL during the day and no change in % time less than 54 mg/dL across 24 h) and greater time in Auto Mode. PROs, including distress, technology attitudes, and hypoglycemia confidence, were not different. AHCL use was associated with improved glucose monitoring satisfaction. Satisfaction was greater in those participants who had more appreciable glycemic benefit and stayed in Auto Mode more often.
Clinical Trial Registration number: NCT03040414.
Get full access to this article
View all available purchase options and get full access to this article.
Disclaimer
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
References
1. Peyrot M, Burns KK, Davies M, et al. Diabetes Attitudes Wishes and Needs 2 (DAWN2): a multinational, multi-stakeholder study of psychosocial issues in diabetes and person-centred diabetes care. Diabetes Res Clin Pract 2013;99:174–184.
2. Polonsky WH, Fisher L, Earles J, et al. Assessing psychosocial distress in diabetes: development of the diabetes distress scale. Diabetes Care 2005;28:626–631.
3. Anderbro TC, Amsberg S, Moberg E, et al. A longitudinal study of fear of hypoglycaemia in adults with type 1 diabetes. Endocrinol Diabetes Metab 2018;1:e00013.
4. Polonsky WH, Fortmann AL. Impact of real-time continuous glucose monitoring data sharing on quality of life and health outcomes in adults with type 1 diabetes. Diabetes Technol Ther 2021;23:195–202.
5. Kovatchev BP, Kollar L, Anderson SM, et al. Evening and overnight closed-loop control versus 24/7 continuous closed-loop control for type 1 diabetes: a randomised crossover trial. Lancet Digit Health 2020;2:e64–e73.
6. Weissberg-Benchell J, Shapiro JB, Hood KK, et al. Assessing patient-reported outcomes for automated insulin delivery systems: the psychometric properties of the INSPIRE measures. Diabet Med 2019;36:644–652.
7. Lal RA, Ekhlaspour L, Hood KK, Buckingham B. Realizing a closed-loop (artificial pancreas) system for the treatment of type 1 diabetes. Endocr Rev 2019;40:1521–1546.
8. Shah VN, Garg SK. Standardized hybrid closed-loop system reporting. Diabetes Technol Ther 2021;23:323–331.
9. Bergenstal RM, Nimri R, Beck RW, et al. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. Lancet 2021;397:208–219.
10. Atlas E, Nimri R, Miller S, et al. MD-logic artificial pancreas system: a pilot study in adults with type 1 diabetes. Diabetes Care 2010;33:1072–1076.
11. Messer LH, Cook PF, Tanenbaum ML, et al. CGM benefits and burdens: two brief measures of continuous glucose monitoring. J Diabetes Sci Technol 2019;13:1135–1141.
12. Polonsky WH, Fisher L, Hessler D, Edelman SV. Investigating hypoglycemic confidence in type 1 and type 2 diabetes. Diabetes Technol Ther 2017;19:131–136.
13. Polonsky WH, Fisher L, Hessler D, Edelman SV. Development of a new measure for assessing glucose monitoring device-related treatment satisfaction and quality of life. Diabetes Technol Ther 2015;17:657–663.
14. Naranjo D, Tanenbaum ML, Iturralde E, Hood KK. Diabetes technology: uptake, outcomes, barriers, and the intersection with distress. J Diabetes Sci Technol 2016;10:852–858.
15. Hood KK, Iturralde E, Rausch J, Weissberg-Benchell J. Preventing diabetes distress in adolescents with type 1 diabetes: results 1 year after participation in the STePS program. Diabetes Care 2018;41:1623–1630.
16. Fisher L, Hessler D, Polonsky WH, et al. T1-REDEEM: a randomized controlled trial to reduce diabetes distress among adults with type 1 diabetes. Diabetes Care 2018;41:1862–1869.
Information & Authors
Information
Published In
Diabetes Technology & Therapeutics
Volume 23 • Issue Number 12 • December 2021
Pages: 857 - 861
PubMed: 34270328
Copyright
Copyright 2021, Mary Ann Liebert, Inc., publishers.
History
Published in print: December 2021
Published online: 25 November 2021
Published ahead of print: 26 October 2021
Published ahead of production: 16 July 2021
Topics
Authors
Authors' Contributions
K.K.H. drafted article. R.J.B. and P.C. performed the statistical analysis. L.M.L., T.D., S.A.W., J.S., D.S., N.B., R.B., A.P., R.N., R.W.B., R.M.B., and M.P., reviewed and edited article.
Author Disclosure Statement
K.K.H. reports grants from Dexcom, personal fees from LifeScan Diabetes Institute and Cercacor, Inc., outside the submitted work. M.P. reports grants from the National Institutes of Health via Health Partners, during the conduct of the study; grants from Insulet, Dexcom, Medtronic, Roche, Eli Lilly, Lexicon, OPKO, and AstraZeneca, grants and personal fees from Novo Nordisk and Sanofi, grants, personal fees, and owning stock from DreaMed Diabetes, personal fees from RSP Systems and Qulab Medical, grants and personal fees from Pfizer, grants and owning stock from Nutriteen Professional and NG Solutions, outside the submitted work. L.M.L. reports grants from the National Institutes of Health during the conduct of the study; personal fees from Sanofi, NovoNordisk, Eli Lilly, Roche, Lifescan, Convatec, Insulogic, Laxmi, Boehringer Ingelheim, Johnson & Johnson, Dexcom, and Insulet, outside the submitted work. D.S. reports grants from the National Institutes of Health, during the conduct of the study; grants from the Leona M. and Harry B. Helmsley Charitable Trust, outside the submitted work. T.D. reports owning stock in DreaMed Ltd. during the conduct of the study; grants and personal fees from AstraZeneca, Dexcom, Boehringer, NovoNordisk, Medtronic, Sanofi, Eli Lilly, and Insulet, outside the submitted work. S.A.W. reports grants from the National Institutes of Health, during the conduct of the study; personal fees from Medtronic, Insulet, Tandem, Eli Lilly, Sanofi, and Zealand, outside the submitted work. R.N. reports grants from National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, nonfinancial support from Medtronic MiniMed, Inc., during the conduct of the study; grants, personal fees, and other from DreaMed Diabetes Ltd., grants and nonfinancial support from Medtronic MiniMed, Inc., nonfinancial support from Dexcom, nonfinancial support from Insulet, grants, and personal fees from Eli Lilly, grants and personal fees from Novonordisk, outside the submitted work. J.S. reports no conflicts of interest. R.J.B. reports no conflicts of interest. P.C. reports personal fees from Dexcom outside the submitted work. R.B. reports grants from the National Institutes of Health, nonfinancial support from Medtronic Minimed, Inc., during the conduct of the study. R. Beck reports grants from National Institutes of Health, nonfinancial support from Medtronic during the conduct of the study; grants, nonfinancial support, and study supplies from Dexcom, consulting fees paid to nonprofit employer from Bigfoot Biomedical, outside the submitted work. R.M.B. reports grants and other from Abbott Diabetes Care, grants and other from Eli Lilly, outside the submitted work. In addition, Dr. M.P. has a patent WO2010097796 issued to DreaMed Diabetes, a patent WO2011039741 issued to DreaMed Diabetes, and a patent WO2019077482 pending.
Funding Information
Research reported in this publication was supported by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under award number (IUC4DK10861) grant provided to Jaeb Center for Health Research and paid to each of the investigator's institutions.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.